Sandoz Group AG (0SAN.L)
LSE · CHF
CHF 82.00 (-0.58%) as of
Key statistics
- 52-week range
- 23.50 – 82.78
- Beta
- 0.46
- Revenue (TTM)
- 11.68B
- Profit margin
- 5.53%
- Volume
- 10.58k
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
- Headquarters
- Basel, Switzerland
- Employees
- 20,000
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.
Related stocks
- GCM RESOURCES PLC ORD 1P (GCM.L)
- CONTINENTAL AG CONTINENTAL ORD (0LQ1.IL)
- NN GROUP NV NN GROUP ORD SHS (0QVV.IL)
- RATIONAL AG RATIONAL ORD SHS (0FRJ.IL)
- BANK OF AMERICA CORP BANK OF AM (0Q16.L)
- SONOVA HOLDING AG SONOVA HOLDIN (0QPY.IL)
- COEUR MINING INC COEUR MINING O (0R0U.L)
- First Trust Vest US Equity Max Buffer UCITS ETF - March Class A USD ACCU (MMAR.L)